Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 October 2021 | Story Xolisa Mnukwa

The University of the Free State (UFS) is currently developing a COVID-19 Regulations and Required Vaccination Policy that all students will have to adhere to in 2022. This policy is being developed to ensure a safe environment for all staff and students upon their return in 2022. 

The university is taking these measures to minimise the risk of exposing staff and students to infection and to enable a safe return to all three UFS campuses next year. However, the university will implement the policy in such a way that it will adequately accommodate individuals who are choosing not to get vaccinated for legitimate reasons.

In order to encourage our students to make the responsible choice by keeping themselves and others safe, the UFS Division of Student Affairs (DSA) is launching a COVID-19 Vaccination Drive that will take place from Monday, 25 October to Wednesday, 27 October 2021.

The programme is as follows:


Monday, 25 October 2021
When: 11:00-14:00
Where: outside Gate 5, UFS Bloemfontein Campus
What: Live performances by students, KovsieFM, KovsieTV, Vox Pops, free UFS branded T-shirts, and giveaways

Wednesday, 27 October 2021
When: 11:00-14:00
Where: Thakaneng Bridge
What: Live performances by local artists and students, KovsieFM, KovsieTV, Vox Pops, free UFS branded T-shirts, and giveaways

COVID-19 Vaccination panel discussion

The Vaccination Drive will conclude on Wednesday, 27 October 2021 with an online panel discussion titled: COVID Vaccination. Informed Youth. Informed Decisions. 
The discussion will start at 16:00 on MS Teams, and students are welcome to join us and ask for advice or clarification about the vaccine from our panel members. The link will be provided soon.

Facilitator: 
Dr Musa Mthombeni, Local TV personality

Panel members include:
Tshepo Moloi, Alumni and Economist representation business sector
Dr Musawenkosi Donia Saurombe, Youngest female PhD holder, lecturer and UFS Alumni
Jerry Thoka, ISRC President
Vusumzi Gqalane, SRC Policy and Transformation on the UFS Vaccination Policy
Asive Dlanjwa, South African Union of Students (SAUS) spokesperson
Victor Sekekete, Free State Cheetahs Rugby Player
Shaxe Khumalo, Entertainment Industry


For more information on the vaccination drive, contact Rethabile Motseki, motsekir@ufs.ac.za or Michelle Nothling at NothlingM@ufs.ac.za 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept